The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent
- 1 August 2001
- journal article
- review article
- Published by Wiley in Obesity Reviews
- Vol. 2 (3) , 199-211
- https://doi.org/10.1046/j.1467-789x.2001.00038.x
Abstract
Summary: Since passage of the Dietary Supplement Health and Education Act of 1994, the sale of herbal dietary supplements containing caffeine and ephedrine for weight loss has become widespread in the United States. Reports of adverse events associated with the use of these non‐prescription supplements have raised concerns in the United States regulatory community. Restricting the use of these products is now being considered. Such restriction should be based upon controlled clinical trials. This review of the literature in Medline relative to the use of caffeine and ephedrine in the treatment of obesity concludes that caffeine and ephedrine are effective in causing weight loss. Caffeine and ephedrine give equivalent weight loss to Diethylpropion and superior weight loss compared to dexfenfluramine. Caffeine and ephedrine have a long history of safe, non‐prescription use. The adverse events accompanying acute dosing are mild and transient. Adverse events with caffeine and ephedrine reach and remain at placebo levels after 4–12 weeks of continuous treatment, but data from randomized trials up to 6 months only are available. Obesity is chronic, requires chronic treatment, its incidence is increasing and it has few effective treatments. The benefits of caffeine and ephedrine in treating obesity appear to outweigh the small associated risks. Restriction of dietary herbal supplements containing caffeine and ephedrine, often with other ingredients, should be based on controlled clinical trials of these products.Keywords
This publication has 63 references indexed in Scilit:
- Regulation of Adipsin and Body Composition in the Monosodium Glutamate (MSG)-Treated MousePhysiology & Behavior, 1996
- Combined Drug Treatment of ObesityObesity Research, 1995
- Pharmacological and Clinical Studies of Ephedrine and Other Thermogenic AgonistsObesity Research, 1995
- Pharmacological Rationale for the Clinical Use of CaffeineDrugs, 1995
- Relationship of dietary intake to hospital admission for coronary heart and vascular disease: the NHANES II national probability study.Journal of the American College of Nutrition, 1993
- Clinical Pharmacokinetics of Drugs in ObesityClinical Pharmacokinetics, 1993
- Energy Utilization in Human ObesityAnnals of the New York Academy of Sciences, 1987
- Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob miceGeneral Pharmacology: The Vascular System, 1986
- Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compoundsLife Sciences, 1984
- Ephedrine reduces weight of viable yellow obese mice (/)Life Sciences, 1981